20357-22-6Relevant articles and documents
Compound with dual inhibitory activity TDO, IDOO1 and application of compound for treating neurodegenerative disease (by machine translation)
-
Paragraph 0135-0136; 0141-0142, (2020/10/06)
The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, or a solvate thereof, which can selectively inhibit TDO, IDOO1, which has a significant inhibitory effect on TDO and/or IDOO1. In addition, the prepared compound has a remarkable anti-tumor effect, has a certain treatment effect on's disease and's disease, and has a good application prospect in the field of medicine preparation. (by machine translation)
Novel access to carbonyl and acetylated compounds: The role of the tetra-: N -butylammonium bromide/sodium nitrite catalyst
Sheykhan, Mehdi,Moafi, Hadi Fallah,Abbasnia, Masoumeh
, p. 51347 - 51355 (2016/06/09)
A novel aerobic oxidation of alcohols without the use of any oxidants was developed. An equimolar catalytic mixture of tetra-n-butylammonium bromide and sodium nitrite catalyzes the aerobic selective oxidation of benzylic alcohols under oxidant-free, base-free and metal-free conditions. The mild reaction conditions allow oxidation of a wide range of benzylic alcohols, chemo-selectively to their carbonyl compounds (68-93% isolated yields). More importantly, high selectivity among different kinds of alcohols (aromatic vs. aliphatic alcohols, primary vs. secondary alcohols as well as alcohols having neutral rings vs. electron-deficient rings) is available by this approach. The method surprisingly switched over to be an efficient acetylation approach in the case of aliphatic alcohols without the use of any transition metal, phosphorous or other toxic reagents or any need for using toxic acyl halides, sulfonyl halides, anhydrides, etc. by the use of only acetic acid as a reagent.
COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
-
Page/Page column 142, (2009/04/25)
Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.